Mepolizumab/omalizumabLack of efficacy following off-label use

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 1998卷 / 1期

关键词：

D O I：

10.1007/s40278-024-54140-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：296 / 296

相关论文

共 50 条

[31] EribulinLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1921 (1) : 135 - 135
[32] ImiquimodLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1920 (1) : 254 - 254
[33] IbrutinibLack of efficacy following off-label use: case report
Reactions Weekly, 2025, 2042 (1) : 209 - 209
[34] InterferonLack of efficacy following off-label use: case report
Reactions Weekly, 2024, 2025 (1) : 231 - 231
[35] VedolizumabLack of efficacy following off-label use: case report
Reactions Weekly, 2023, 1938 (1) : 1250 - 1250
[36] TocilizumabLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1887 (1) : 643 - 643
[37] DexamethasoneLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1936 (1) : 195 - 195
[38] ApixabanLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1935 (1) : 89 - 89
[39] Dexamethasone/remdesivir/tocilizumabLack of efficacy following off-label use
Reactions Weekly, 2024, 1999 (1) : 147 - 147
[40] CabazitaxelLack of efficacy following off-label use: case report
Reactions Weekly, 2023, 1980 (1) : 102 - 102

← 1 2 3 4 5 →